Cargando…
Allogeneic hematopoietic stem-cell transplantation for myelofibrosis
Myelofibrosis is one of the Philadelphia chromosome (Ph)-negative myeloproliferative neoplasms with heterogeneous clinical course. Though many treatment options, including Janus kinase (JAK) inhibitors, have provided clinical benefits and improved survival, allogeneic hematopoietic stem-cell transpl...
Autores principales: | Zhang, Lining, Yang, Fan, Feng, Sizhou |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7019406/ https://www.ncbi.nlm.nih.gov/pubmed/32110286 http://dx.doi.org/10.1177/2040620720906002 |
Ejemplares similares
-
The Use of Allogeneic Hematopoietic Stem Cell Transplantation in Primary Myelofibrosis
por: Wolfe, Heather R., et al.
Publicado: (2022) -
Advances in the understanding of poor graft function following allogeneic hematopoietic stem-cell transplantation
por: Chen, Juan, et al.
Publicado: (2020) -
Management of Epstein–Barr virus-related post-transplant lymphoproliferative disorder after allogeneic hematopoietic stem cell transplantation
por: Liu, Li, et al.
Publicado: (2020) -
Long-term outcome after allogeneic hematopoietic cell transplantation for myelofibrosis
por: Robin, Marie, et al.
Publicado: (2019) -
Allogeneic Hematopoietic Stem Cell Transplantation for Post-essential Thrombocythemia and Post-polycythemia Vera Myelofibrosis
por: Murata, Makoto, et al.
Publicado: (2020)